Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Month: March 2023
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue…
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue…
Windtree Regains Compliance with Nasdaq
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
Windtree Regains Compliance with Nasdaq
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and…
Atavistik Bio Announces Publication in Science by Co-Founder Jared Rutter Describing Foundational Technology for its Atavistik Metabolite-Protein Screening (AMPS) Platform
MIDAS (mass spectrometry integrated with equilibrium dialysis for the discovery of allostery systematically), in-licensed and…
Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND…
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND…
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (p CARSON CITY, Nev., March 13,…
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (p CARSON CITY, Nev., March 13,…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future…
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (“First Wave…
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (“First Wave…